OKYO Pharma Limited (OKYO)
NASDAQ: OKYO · Real-Time Price · USD
2.250
-0.020 (-0.88%)
At close: Sep 4, 2025, 4:00 PM
2.260
+0.010 (0.44%)
After-hours: Sep 4, 2025, 6:15 PM EDT
OKYO Pharma Employees
OKYO Pharma had 4 employees as of March 31, 2025. The number of employees increased by 1 or 33.33% compared to the previous year.
Employees
4
Change (1Y)
1
Growth (1Y)
33.33%
Revenue / Employee
n/a
Profits / Employee
-$1,176,573
Market Cap
84.62M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 4 | 1 | 33.33% |
| Mar 31, 2024 | 3 | -5 | -62.50% |
| Mar 31, 2023 | 8 | 1 | 14.29% |
| Mar 31, 2022 | 7 | 1 | 16.67% |
| Mar 31, 2021 | 6 | 2 | 50.00% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
OKYO News
- 7 weeks ago - OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain - GlobeNewsWire
- 3 months ago - Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited - Accesswire
- 3 months ago - OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit - GlobeNewsWire
- 4 months ago - OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain - GlobeNewsWire
- 5 months ago - OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod - GlobeNewsWire
- 7 months ago - OKYO Pharma Announces Chairman and CEO Acquire Shares - GlobeNewsWire
- 7 months ago - Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited - Accesswire
- 10 months ago - MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Accesswire